---
type: "Topics"
locale: "en"
url: "https://longbridge.com/en/topics/42511704.md"
description: "$Viking Therap(VKTX.US) rose significantly today, as its weight-loss drug pipeline took another step forward – its second candidate, VK3019, just entered a Phase 1 first-in-human single ascending dose trial, while the Phase 3 trials for its main drug, VK2735 (both oral and injectable), are also progressing.Whenever there's a new data point in the GLP-1 space, $Viking Therap(VKTX.US) has always shown high volatility. This rally is more about pipeline expectations being realized rather than pure sentiment."
datetime: "2026-07-08T10:40:16.000Z"
locales:
  - [en](https://longbridge.com/en/topics/42511704.md)
  - [zh-CN](https://longbridge.com/zh-CN/topics/42511704.md)
  - [zh-HK](https://longbridge.com/zh-HK/topics/42511704.md)
author: "[袋鼠](https://longbridge.com/en/profiles/27248405.md)"
---

# $Viking Therap(VKTX.US) rose significantly today, …


### Related Stocks

- [VKTX.US](https://longbridge.com/en/quote/VKTX.US.md)